Global Human Bacterial Vaccine Market

Human Bacterial Vaccine Comprehensive Study by Administration (Oral, Intramuscular, Intradermal, Subcutaneous, Intranasal), Category (Live Attenuated, Inactivated, Sub-Unit, Toxoid Vaccine), Indication (Polio, Covid-19, Herpes Zoster, Influenza, Pneumococcal Disease, Others), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2030

Human Bacterial Vaccine Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Human Bacterial Vaccine Market Scope
Human bacterial vaccine vectors have been widely employed to transmit and express heterologous vaccine antigens in order to protect against cancer and other infectious diseases. Bacterial vaccinations contain microorganisms that have been killed or attenuated in order to stimulate the immune system. Antibodies are produced in response to that specific bacterium, and they help to avoid bacterial infection in the future. Tuberculosis vaccination is an example of a bacterial vaccine. Live bacterial vaccines have the advantage of being able to express many antigens, being simple to mass produce, being able to be administered orally or intranasally, and eliciting powerful immune responses. Toxoids, subunit vaccinations, killed whole cell vaccines, and live attenuated vaccines are some of the numerous types of bacterial vaccines.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledPfizer (United States), Serum Institute of India. (India), Lonza Group AG (Switzerland), Thermo Fisher Scientific (United States), Merck KGaA (Germany), Cytiva (United States), HiMedia Laboratories. (India), PromoCell (Germany), Valneva SE. (France) and Pall Corporation. (United States)
CAGR8.2%


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Human Bacterial Vaccine market throughout the predicted period.

Pfizer (United States), Serum Institute of India. (India), Lonza Group AG (Switzerland), Thermo Fisher Scientific (United States), Merck KGaA (Germany), Cytiva (United States), HiMedia Laboratories. (India), PromoCell (Germany), Valneva SE. (France) and Pall Corporation. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Lonza Group AG (Switzerland), Sartorius AG (Germany) and PerkinElmer Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Human Bacterial Vaccine market by Type and Region with country level break-up.

On the basis of geography, the market of Human Bacterial Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies

On 8th June, 2021 – Pfizer Received U.S. FDA Approval for PREVNAR 20, Pfizer’s Pneumococcal 20-Valent Conjugate Vaccine for Prevention of Invasive Disease and Pneumonia Caused by the 20 Streptococcus Pneumoniae (Pneumococcus) Serotypes in Vaccine in Adults Ages 18 Years and Older.


Influencing Trend:
Rising Geriatric Population

Market Growth Drivers:
Prevalence of Infectious Diseases and Viruses and Growing Emphasis on Immunization Programs

Challenges:
Fierce Competitive Pressure and Lack of Skilled Professionals

Restraints:
High Cost of Vaccine Development

Opportunities:
Increasing Investment in Bacterial Vaccine R&D and Growth in Healthcare Infrastructure Across Emerging Regions

Key Target Audience
Human Bacterial Vaccine Manufactures, New Entrants and investors, Human Bacterial Vaccine Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Administration
  • Oral
  • Intramuscular
  • Intradermal
  • Subcutaneous
  • Intranasal

By Category
  • Live Attenuated
  • Inactivated
  • Sub-Unit
  • Toxoid Vaccine

By Indication
  • Polio
  • Covid-19
  • Herpes Zoster
  • Influenza
  • Pneumococcal Disease
  • Others

By End User
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Infectious Diseases and Viruses
      • 3.2.2. Growing Emphasis on Immunization Programs
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
      • 3.3.2. Lack of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Bacterial Vaccine, by Administration, Category, Indication, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Bacterial Vaccine (Value)
      • 5.2.1. Global Human Bacterial Vaccine by: Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Intramuscular
        • 5.2.1.3. Intradermal
        • 5.2.1.4. Subcutaneous
        • 5.2.1.5. Intranasal
      • 5.2.2. Global Human Bacterial Vaccine by: Category (Value)
        • 5.2.2.1. Live Attenuated
        • 5.2.2.2. Inactivated
        • 5.2.2.3. Sub-Unit
        • 5.2.2.4. Toxoid Vaccine
      • 5.2.3. Global Human Bacterial Vaccine by: Indication (Value)
        • 5.2.3.1. Polio
        • 5.2.3.2. Covid-19
        • 5.2.3.3. Herpes Zoster
        • 5.2.3.4. Influenza
        • 5.2.3.5. Pneumococcal Disease
        • 5.2.3.6. Others
      • 5.2.4. Global Human Bacterial Vaccine by: End User (Value)
        • 5.2.4.1. Pediatric
        • 5.2.4.2. Adult
        • 5.2.4.3. Geriatric
      • 5.2.5. Global Human Bacterial Vaccine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Human Bacterial Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Serum Institute of India. (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza Group AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck KGaA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cytiva (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. HiMedia Laboratories. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. PromoCell (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Valneva SE. (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pall Corporation. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Human Bacterial Vaccine Sale, by Administration, Category, Indication, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Bacterial Vaccine (Value)
      • 7.2.1. Global Human Bacterial Vaccine by: Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Intramuscular
        • 7.2.1.3. Intradermal
        • 7.2.1.4. Subcutaneous
        • 7.2.1.5. Intranasal
      • 7.2.2. Global Human Bacterial Vaccine by: Category (Value)
        • 7.2.2.1. Live Attenuated
        • 7.2.2.2. Inactivated
        • 7.2.2.3. Sub-Unit
        • 7.2.2.4. Toxoid Vaccine
      • 7.2.3. Global Human Bacterial Vaccine by: Indication (Value)
        • 7.2.3.1. Polio
        • 7.2.3.2. Covid-19
        • 7.2.3.3. Herpes Zoster
        • 7.2.3.4. Influenza
        • 7.2.3.5. Pneumococcal Disease
        • 7.2.3.6. Others
      • 7.2.4. Global Human Bacterial Vaccine by: End User (Value)
        • 7.2.4.1. Pediatric
        • 7.2.4.2. Adult
        • 7.2.4.3. Geriatric
      • 7.2.5. Global Human Bacterial Vaccine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Bacterial Vaccine: by Administration(USD Million)
  • Table 2. Human Bacterial Vaccine Oral , by Region USD Million (2018-2023)
  • Table 3. Human Bacterial Vaccine Intramuscular , by Region USD Million (2018-2023)
  • Table 4. Human Bacterial Vaccine Intradermal , by Region USD Million (2018-2023)
  • Table 5. Human Bacterial Vaccine Subcutaneous , by Region USD Million (2018-2023)
  • Table 6. Human Bacterial Vaccine Intranasal , by Region USD Million (2018-2023)
  • Table 7. Human Bacterial Vaccine: by Category(USD Million)
  • Table 8. Human Bacterial Vaccine Live Attenuated , by Region USD Million (2018-2023)
  • Table 9. Human Bacterial Vaccine Inactivated , by Region USD Million (2018-2023)
  • Table 10. Human Bacterial Vaccine Sub-Unit , by Region USD Million (2018-2023)
  • Table 11. Human Bacterial Vaccine Toxoid Vaccine , by Region USD Million (2018-2023)
  • Table 12. Human Bacterial Vaccine: by Indication(USD Million)
  • Table 13. Human Bacterial Vaccine Polio , by Region USD Million (2018-2023)
  • Table 14. Human Bacterial Vaccine Covid-19 , by Region USD Million (2018-2023)
  • Table 15. Human Bacterial Vaccine Herpes Zoster , by Region USD Million (2018-2023)
  • Table 16. Human Bacterial Vaccine Influenza , by Region USD Million (2018-2023)
  • Table 17. Human Bacterial Vaccine Pneumococcal Disease , by Region USD Million (2018-2023)
  • Table 18. Human Bacterial Vaccine Others , by Region USD Million (2018-2023)
  • Table 19. Human Bacterial Vaccine: by End User(USD Million)
  • Table 20. Human Bacterial Vaccine Pediatric , by Region USD Million (2018-2023)
  • Table 21. Human Bacterial Vaccine Adult , by Region USD Million (2018-2023)
  • Table 22. Human Bacterial Vaccine Geriatric , by Region USD Million (2018-2023)
  • Table 23. South America Human Bacterial Vaccine, by Country USD Million (2018-2023)
  • Table 24. South America Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 25. South America Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 26. South America Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 27. South America Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 28. Brazil Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 29. Brazil Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 30. Brazil Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 31. Brazil Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 32. Argentina Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 33. Argentina Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 34. Argentina Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 35. Argentina Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 36. Rest of South America Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 37. Rest of South America Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 38. Rest of South America Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 39. Rest of South America Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 40. Asia Pacific Human Bacterial Vaccine, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 42. Asia Pacific Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 43. Asia Pacific Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 44. Asia Pacific Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 45. China Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 46. China Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 47. China Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 48. China Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 49. Japan Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 50. Japan Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 51. Japan Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 52. Japan Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 53. India Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 54. India Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 55. India Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 56. India Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 57. South Korea Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 58. South Korea Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 59. South Korea Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 60. South Korea Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 61. Taiwan Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 62. Taiwan Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 63. Taiwan Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 64. Taiwan Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 65. Australia Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 66. Australia Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 67. Australia Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 68. Australia Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 73. Europe Human Bacterial Vaccine, by Country USD Million (2018-2023)
  • Table 74. Europe Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 75. Europe Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 76. Europe Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 77. Europe Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 78. Germany Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 79. Germany Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 80. Germany Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 81. Germany Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 82. France Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 83. France Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 84. France Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 85. France Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 86. Italy Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 87. Italy Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 88. Italy Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 89. Italy Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 90. United Kingdom Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 91. United Kingdom Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 92. United Kingdom Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 93. United Kingdom Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 94. Netherlands Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 95. Netherlands Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 96. Netherlands Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 97. Netherlands Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 98. Rest of Europe Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 99. Rest of Europe Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 100. Rest of Europe Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 101. Rest of Europe Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 102. MEA Human Bacterial Vaccine, by Country USD Million (2018-2023)
  • Table 103. MEA Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 104. MEA Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 105. MEA Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 106. MEA Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 107. Middle East Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 108. Middle East Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 109. Middle East Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 110. Middle East Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 111. Africa Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 112. Africa Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 113. Africa Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 114. Africa Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 115. North America Human Bacterial Vaccine, by Country USD Million (2018-2023)
  • Table 116. North America Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 117. North America Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 118. North America Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 119. North America Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 120. United States Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 121. United States Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 122. United States Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 123. United States Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 124. Canada Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 125. Canada Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 126. Canada Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 127. Canada Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 128. Mexico Human Bacterial Vaccine, by Administration USD Million (2018-2023)
  • Table 129. Mexico Human Bacterial Vaccine, by Category USD Million (2018-2023)
  • Table 130. Mexico Human Bacterial Vaccine, by Indication USD Million (2018-2023)
  • Table 131. Mexico Human Bacterial Vaccine, by End User USD Million (2018-2023)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Human Bacterial Vaccine: by Administration(USD Million)
  • Table 143. Human Bacterial Vaccine Oral , by Region USD Million (2025-2030)
  • Table 144. Human Bacterial Vaccine Intramuscular , by Region USD Million (2025-2030)
  • Table 145. Human Bacterial Vaccine Intradermal , by Region USD Million (2025-2030)
  • Table 146. Human Bacterial Vaccine Subcutaneous , by Region USD Million (2025-2030)
  • Table 147. Human Bacterial Vaccine Intranasal , by Region USD Million (2025-2030)
  • Table 148. Human Bacterial Vaccine: by Category(USD Million)
  • Table 149. Human Bacterial Vaccine Live Attenuated , by Region USD Million (2025-2030)
  • Table 150. Human Bacterial Vaccine Inactivated , by Region USD Million (2025-2030)
  • Table 151. Human Bacterial Vaccine Sub-Unit , by Region USD Million (2025-2030)
  • Table 152. Human Bacterial Vaccine Toxoid Vaccine , by Region USD Million (2025-2030)
  • Table 153. Human Bacterial Vaccine: by Indication(USD Million)
  • Table 154. Human Bacterial Vaccine Polio , by Region USD Million (2025-2030)
  • Table 155. Human Bacterial Vaccine Covid-19 , by Region USD Million (2025-2030)
  • Table 156. Human Bacterial Vaccine Herpes Zoster , by Region USD Million (2025-2030)
  • Table 157. Human Bacterial Vaccine Influenza , by Region USD Million (2025-2030)
  • Table 158. Human Bacterial Vaccine Pneumococcal Disease , by Region USD Million (2025-2030)
  • Table 159. Human Bacterial Vaccine Others , by Region USD Million (2025-2030)
  • Table 160. Human Bacterial Vaccine: by End User(USD Million)
  • Table 161. Human Bacterial Vaccine Pediatric , by Region USD Million (2025-2030)
  • Table 162. Human Bacterial Vaccine Adult , by Region USD Million (2025-2030)
  • Table 163. Human Bacterial Vaccine Geriatric , by Region USD Million (2025-2030)
  • Table 164. South America Human Bacterial Vaccine, by Country USD Million (2025-2030)
  • Table 165. South America Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 166. South America Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 167. South America Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 168. South America Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 169. Brazil Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 170. Brazil Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 171. Brazil Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 172. Brazil Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 173. Argentina Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 174. Argentina Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 175. Argentina Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 176. Argentina Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 177. Rest of South America Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 178. Rest of South America Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 179. Rest of South America Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 180. Rest of South America Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 181. Asia Pacific Human Bacterial Vaccine, by Country USD Million (2025-2030)
  • Table 182. Asia Pacific Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 183. Asia Pacific Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 184. Asia Pacific Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 185. Asia Pacific Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 186. China Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 187. China Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 188. China Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 189. China Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 190. Japan Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 191. Japan Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 192. Japan Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 193. Japan Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 194. India Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 195. India Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 196. India Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 197. India Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 198. South Korea Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 199. South Korea Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 200. South Korea Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 201. South Korea Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 202. Taiwan Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 203. Taiwan Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 204. Taiwan Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 205. Taiwan Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 206. Australia Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 207. Australia Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 208. Australia Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 209. Australia Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 212. Rest of Asia-Pacific Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 213. Rest of Asia-Pacific Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 214. Europe Human Bacterial Vaccine, by Country USD Million (2025-2030)
  • Table 215. Europe Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 216. Europe Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 217. Europe Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 218. Europe Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 219. Germany Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 220. Germany Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 221. Germany Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 222. Germany Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 223. France Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 224. France Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 225. France Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 226. France Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 227. Italy Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 228. Italy Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 229. Italy Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 230. Italy Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 231. United Kingdom Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 232. United Kingdom Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 233. United Kingdom Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 234. United Kingdom Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 235. Netherlands Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 236. Netherlands Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 237. Netherlands Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 238. Netherlands Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 239. Rest of Europe Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 240. Rest of Europe Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 241. Rest of Europe Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 242. Rest of Europe Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 243. MEA Human Bacterial Vaccine, by Country USD Million (2025-2030)
  • Table 244. MEA Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 245. MEA Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 246. MEA Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 247. MEA Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 248. Middle East Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 249. Middle East Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 250. Middle East Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 251. Middle East Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 252. Africa Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 253. Africa Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 254. Africa Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 255. Africa Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 256. North America Human Bacterial Vaccine, by Country USD Million (2025-2030)
  • Table 257. North America Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 258. North America Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 259. North America Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 260. North America Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 261. United States Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 262. United States Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 263. United States Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 264. United States Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 265. Canada Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 266. Canada Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 267. Canada Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 268. Canada Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 269. Mexico Human Bacterial Vaccine, by Administration USD Million (2025-2030)
  • Table 270. Mexico Human Bacterial Vaccine, by Category USD Million (2025-2030)
  • Table 271. Mexico Human Bacterial Vaccine, by Indication USD Million (2025-2030)
  • Table 272. Mexico Human Bacterial Vaccine, by End User USD Million (2025-2030)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Bacterial Vaccine: by Administration USD Million (2018-2023)
  • Figure 5. Global Human Bacterial Vaccine: by Category USD Million (2018-2023)
  • Figure 6. Global Human Bacterial Vaccine: by Indication USD Million (2018-2023)
  • Figure 7. Global Human Bacterial Vaccine: by End User USD Million (2018-2023)
  • Figure 8. South America Human Bacterial Vaccine Share (%), by Country
  • Figure 9. Asia Pacific Human Bacterial Vaccine Share (%), by Country
  • Figure 10. Europe Human Bacterial Vaccine Share (%), by Country
  • Figure 11. MEA Human Bacterial Vaccine Share (%), by Country
  • Figure 12. North America Human Bacterial Vaccine Share (%), by Country
  • Figure 13. Global Human Bacterial Vaccine share by Players 2023 (%)
  • Figure 14. Global Human Bacterial Vaccine share by Players (Top 3) 2023(%)
  • Figure 15. Global Human Bacterial Vaccine share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2023
  • Figure 19. Serum Institute of India. (India) Revenue, Net Income and Gross profit
  • Figure 20. Serum Institute of India. (India) Revenue: by Geography 2023
  • Figure 21. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Lonza Group AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 24. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 25. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 27. Cytiva (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cytiva (United States) Revenue: by Geography 2023
  • Figure 29. HiMedia Laboratories. (India) Revenue, Net Income and Gross profit
  • Figure 30. HiMedia Laboratories. (India) Revenue: by Geography 2023
  • Figure 31. PromoCell (Germany) Revenue, Net Income and Gross profit
  • Figure 32. PromoCell (Germany) Revenue: by Geography 2023
  • Figure 33. Valneva SE. (France) Revenue, Net Income and Gross profit
  • Figure 34. Valneva SE. (France) Revenue: by Geography 2023
  • Figure 35. Pall Corporation. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pall Corporation. (United States) Revenue: by Geography 2023
  • Figure 37. Global Human Bacterial Vaccine: by Administration USD Million (2025-2030)
  • Figure 38. Global Human Bacterial Vaccine: by Category USD Million (2025-2030)
  • Figure 39. Global Human Bacterial Vaccine: by Indication USD Million (2025-2030)
  • Figure 40. Global Human Bacterial Vaccine: by End User USD Million (2025-2030)
  • Figure 41. South America Human Bacterial Vaccine Share (%), by Country
  • Figure 42. Asia Pacific Human Bacterial Vaccine Share (%), by Country
  • Figure 43. Europe Human Bacterial Vaccine Share (%), by Country
  • Figure 44. MEA Human Bacterial Vaccine Share (%), by Country
  • Figure 45. North America Human Bacterial Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Serum Institute of India. (India)
  • Lonza Group AG (Switzerland)
  • Thermo Fisher Scientific (United States)
  • Merck KGaA (Germany)
  • Cytiva (United States)
  • HiMedia Laboratories. (India)
  • PromoCell (Germany)
  • Valneva SE. (France)
  • Pall Corporation. (United States)
Additional players considered in the study are as follows:
Lonza Group AG (Switzerland) , Sartorius AG (Germany) , PerkinElmer Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 211 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Bacterial Vaccine Market Quantitative research analysis
Global Human Bacterial Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Human Bacterial Vaccine Market are by end use application [].
The Human Bacterial Vaccine Market is gaining popularity and expected to see strong valuation by 2030.
  • Prevalence of Infectious Diseases and Viruses
  • Growing Emphasis on Immunization Programs

Know More About Global Human Bacterial Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Period Protein Comprehensive Study by Application (Pharmaceuticals, Supplements, Others), Category (PER 1, PER 2, PER 3, Others) Players and Region - Global Market Outlook to 2026
$ 3500
Microrna Reverse Transcription Comprehensive Study by Type (Kits & reagents, Instruments, Consumables), Application (Kidney disease, Cancer, Cardiovascular disease, Neurological disease, Other), Samp...
$ 3750
Vector Based RNAi Comprehensive Study by Type (MicroRNA (miRNA), Small interfering RNA (siRNA)), Application (Neurological Disorders, Oncology, Ocular Disorders, Hepatitis B and C, Autoimmune Hepatit...
$ 3450
Parry Romberg Syndrome Comprehensive Study by End Use (Hospital, Specialty Clinic, Others), Dignosis (Physical Examination, MRI Scan, Serum Test, Others), Treatment Type (Drug Treatment, Surgery, Oth...
$ 3350
Wheat Germ Agglutinin Comprehensive Study by Type (Conjugate, Test Kitx, Other), Application (Label Cell Membranes, Fibrotic Scar Tissue, Imaging And Analysis), Isoforms (WGA1, WGA2, WGA3) Players an...
$ 3500
Crispr Genomic Cure Comprehensive Study by Application (Biomedical, Agricultural), Disease (Cancer, Blood disorders, Blindness, AIDS, Cystic fibrosis, Muscular dystrophy, Huntington's disease, Covid-...
$ 3650